Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02121353

Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration

A Pilot Phase 1/2, Double Blind, Parallel Group, Controlled Study of the Safety, Tolerability and Preliminary Efficacy Evaluation of Intravitreally Administered Pfenex Ranibizumab Biosimilar Versus Lucentis for the Treatment of Neovascular AMD

Sponsor: Pfenex, Inc

Conditions Age Related Macular Degeneration (AMD)

Interventions Lucentis PF582

Updated 6 times since 2017 Last updated: May 9, 2016 Started: Nov 30, 2013 Primary completion: Jan 31, 2016 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02121353, this PHASE1/PHASE2 trial focuses on Age Related Macular Degeneration (AMD) and remains completed. Sponsored by Pfenex, Inc, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfenex, Inc

Data source: Pfenex, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Auckland, New Zealand
• Remuera, New Zealand